FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

(2021) Edmond Chiche et al.   Blood Advances

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia

(2021) S. Fodil et al.   LEUKEMIA & LYMPHOMA

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

(2021) Abhishek Maiti et al.   Blood Cancer Journal

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

(2021) Mahesh Swaminathan et al.   HAEMATOLOGICA

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML

(2020) Stephen S.Y. Lam et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

(2020) Ahmad I. Antar et al.   LEUKEMIA

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

(2020) Raghuveer Singh Mali et al.   HAEMATOLOGICA

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

(2020) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

(2020) Li Xuan et al.   LANCET ONCOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

(2020) Musa Yilmaz et al.   Journal of Hematology & Oncology

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

(2020) Richard T. Maziarz et al.   BONE MARROW TRANSPLANTATION

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

(2019) Haijiao Zhang et al.   Nature Communications

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia

(2019) Christine M. McMahon et al.   Cancer Discovery

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

(2019) Jorge E Cortes et al.   LANCET ONCOLOGY

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

(2019) Alexander E. Perl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)

(2018) Maro Ohanian et al.   AMERICAN JOURNAL OF HEMATOLOGY

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

(2018) Jeffrey E. Lancet et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

(2017) Max J. Gordon et al.   LEUKEMIA RESEARCH

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Future of Targeting FLT3 Activation in AML

(2017) Mark B. Leick et al.   Current Hematologic Malignancy Reports

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

(2016) Lauren Y. Lee et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

(2015) Paolo Strati et al.   AMERICAN JOURNAL OF HEMATOLOGY

Secondary mutations as mediators of resistance to targeted therapy in leukemia

(2015) N. Daver et al.   BLOOD

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

(2013) Casey B. Williams et al.   PHARMACOTHERAPY

Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis

(2012) Salut Brunet et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

(2012) A S Moore et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia

(2009) S. Meshinchi et al.   CLINICAL CANCER RESEARCH